Drug intelligence / Profile preview

ABX-IL8

Development stage: Phase 2
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

ABX-IL8 is a neutralizing antibody developed by Abgenix. It has been investigated in clinical trials to determine its efficacy in improving shortness of breath. Preclinical studies have also explored its role in inhibiting angiogenesis and reducing metastatic incidence in melanoma by targeting interleukin 8 (IL-8).

Targets

IL8 (C-X-C Motif Chemokine Ligand 8)

Beyond the preview

Go deeper on ABX-IL8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABX-IL8.

Explore the full profile